Heran Ma1,2, Yi Tan1,2, Dingke Wen1, Na Qu1, Qunfang Kong1, Kun Li3, Suxia Ma4, Jianhui Zhang1. 1. Qilu Cell Therapy Technology Co., Ltd, Jinan, China. 2. Shandong Yinfeng Life Science Research Institute, Jinan, China. 3. Department of Digestion, First Affiliated Hospital of Shandong First Medical University, Jinan, China. 4. Heze Municipal Hospital, Heze, Shandong, China.
Abstract
INTRODUCTION: To deliver specific antigens in tumor immunotherapy, tumor cell lysates are commonly used to sensitize dendritic cells (DCs). However, the lysates possess low immunogenicity and contain many types of non-tumor-related antigens, which may induce autoimmune diseases. Tumor antigen peptides can provide high specificity but are expensive and their short half-lives limit their clinical application. METHODS: In this study, we used adenovirus to transfer the carbonic anhydrase IX (CA9) gene into DCs to generate specificity to renal cell carcinoma (RCC) which is the most common space-occupying lesion in humans. Inhibition of antigen presentation attenuators (iAPA) technology was also used to enhance the DC delivery capacity. Finally, DCs were co-cultured with cytotoxic T-lymphocytes (CTLs) and the anti-tumor effects were evaluated. RESULTS: The results showed that the CA9-DC-CTLs possessed a high specificity to CA9-positive cells and showed stronger anti-tumor activity than GFP-DC-CTLs both in vitro and in vivo. DISCUSSION: These findings may suggest a novel treatment option for RCC.
INTRODUCTION: To deliver specific antigens in tumor immunotherapy, tumor cell lysates are commonly used to sensitize dendritic cells (DCs). However, the lysates possess low immunogenicity and contain many types of non-tumor-related antigens, which may induce autoimmune diseases. Tumor antigen peptides can provide high specificity but are expensive and their short half-lives limit their clinical application. METHODS: In this study, we used adenovirus to transfer the carbonic anhydrase IX (CA9) gene into DCs to generate specificity to renal cell carcinoma (RCC) which is the most common space-occupying lesion in humans. Inhibition of antigen presentation attenuators (iAPA) technology was also used to enhance the DC delivery capacity. Finally, DCs were co-cultured with cytotoxic T-lymphocytes (CTLs) and the anti-tumor effects were evaluated. RESULTS: The results showed that the CA9-DC-CTLs possessed a high specificity to CA9-positive cells and showed stronger anti-tumor activity than GFP-DC-CTLs both in vitro and in vivo. DISCUSSION: These findings may suggest a novel treatment option for RCC.
Authors: Benyue Zhang; Benoit Chassaing; Zhenda Shi; Robin Uchiyama; Zhan Zhang; Timothy L Denning; Sue E Crawford; Andrea J Pruijssers; Jason A Iskarpatyoti; Mary K Estes; Terence S Dermody; Wenjun Ouyang; Ifor R Williams; Matam Vijay-Kumar; Andrew T Gewirtz Journal: Science Date: 2014-11-14 Impact factor: 47.728
Authors: A Flores-Langarica; K Müller Luda; E K Persson; C N Cook; S Bobat; J L Marshall; M W Dahlgren; K Hägerbrand; K M Toellner; M D Goodall; D R Withers; I R Henderson; B Johansson Lindbom; A F Cunningham; W W Agace Journal: Mucosal Immunol Date: 2017-12-20 Impact factor: 7.313
Authors: L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus Journal: J Exp Med Date: 1996-01-01 Impact factor: 14.307